We are developing a 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24), which can provide more comprehensive protection for the younger age group. In preclinical animal studies, our investigational PCV24 has demonstrated excellent immunogenicity, inducing a robust immune response against all 24 serotypes. Specifically, in the same study, the geometric mean titer (GMT) of antibodies elicited by our investigational PCV24 was equivalent to or (for several serotypes) higher than that induced by the marketed PCV20 vaccine. We believe that the investigational PPSV23 and PCV24 can form a product portfolio with synergistic effects for the prevention of pneumococcal diseases, underscoring our commitment to advancing vaccine technology while seizing significant market opportunities. We plan to complete preclinical studies in 2025 and intend to submit a pre-IND (Investigational New Drug) application to the National Medical Products Administration (NMPA) in the first quarter of 2026.

For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.